Health

Global Parkinson’s Disease Market (COVID – 19 Updates) 2020 to See Stunning Growth Worldwide, Leading Players -GlaxoSmithKline Plc, Acorda Therapeutics, Inc, Amneal Pharmaceuticals LLC

Global Parkinson’s Disease Market

DBMR has added a new report titled Global Parkinson’s Disease Market with data Tables for historical and forecast years represented with Chats & Graphs spread through Pages with easy to understand detailed analysis. This Global Parkinson’s Disease Market report underlines the specific study of the industry which explains what the market definition, classifications, applications, engagements, and global industry trends are. The market data analysed and evaluated in this Global Parkinson’s Disease Market report makes you achieve the business goals and objectives in preset time frame. It highlights a wide-ranging evaluation of the market’s growth prospects and restrictions. This report is very useful to all sizes of business which makes it simpler to take informed decisions regarding different facets of industry. Global Parkinson’s Disease Market report truly acts as a backbone to the business.

Global parkinson’s disease market is rising gradually to an estimated value of USD 9.7 Billion by 2026 registering a healthy CAGR of 12.2% in the forecast period of 2019-2026. This significant rise in market value can increase research development initiatives to launching novel therapies.

Download Exclusive Sample Report (350 Pages PDF with All Related Graphs & Charts) @
https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-parkinsons-disease-market&pm

Few of the major competitors currently working in the global parkinson’s disease market are, Teva Pharmaceutical Industries Ltd, GlaxoSmithKline Plc, Acorda Therapeutics, Inc, Amneal Pharmaceuticals LLC , Imugene Limited,  Immutep, F. Hoffmann-La Roche Ltd, Osmotica Pharmaceuticals plc, Vertical Pharmaceuticals, LLC,  Adamas Pharmaceuticals, Inc, Novartis AG, Eli Lilly and Company, AbbVie Inc  and few among others.

Unlock new opportunities in Global Parkinson’s Disease Market; the latest release from Data Bridge Market Research highlights the key market trends significant to the growth prospects, Let us know if any specific players or list of players needs to consider to gain better insights.

A skilful set of analysts, statisticians, research experts, forecasters, and economists work carefully to build this Global Parkinson’s Disease Market research report for the businesses seeking a prospective growth. These parameters mainly include latest trends, market segmentation, new market opening, industry forecasting, target market analysis, future directions, opportunity identification, strategic analysis, insights and innovation. This market research report makes you knowledgeable about strategic analysis of mergers, expansions, acquisitions, partnerships, and investment. Global Parkinson’s Disease Market research analysis lends a hand to businesses for the planning of production, product launches, costing, inventory, purchasing and marketing strategies.

Market Definition: Global Parkinson’s Disease Market

Parkinson’s disease is chronic and progressive neurodegenerative disorders that affects dopamine producing neurons in central nervous system. Parkinson’s disease tends to develops in brain over many years. The patient with Parkinson’s disease experience tremor, slow movement, rigid muscle, impaired posture and balance, loss of automatic movements, slurry speech and others.

According to the Clinical Practice Research Data link summary report 2018, it is identified that there were 145,519 prevalence cases of patient with age 20 and above with Parkinson’s disease in UK seen in the year 2018. The estimation incidence cases were 18,461 in patient aged above 45 or over. This significant rise in patient number acts as a driver for the growth of Parkinson’s disease Market.

Competitive Analysis: Global Parkinson’s Disease Market

Global parkinson’s disease market is highly fragmented and the major players have used various strategies such as new product launches, expansions, agreements, joint ventures, partnerships, acquisitions, and others to increase their footprints in this market. The report includes market shares of parkinson’s disease market for Global, Europe, North America, Asia-Pacific, South America and Middle East & Africa.

Global Parkinson’s Disease Market By Type (Drug-induced parkinsonism, Vascular parkinsonism, Normal pressure hydrocephalus (NSA), Corticobasal degeneration (CBD), Progressive supranuclear palsy (PSP), Multiple system atrophy (MSA), Idiopathic Parkinson’s and Others), Mechanism of Cation type( Dopamine agonists, Monoamine oxidase B (MAO-B) inhibitors, Catechol-O-methyltransferase (COMT) inhibitors, Adenosine A2 receptor antagonist), Therapy Type (Medication, Deep brain stimulation and Others), Drug Type (Amantadine, Safinamide, Brivaracetam, Pimavanserin, Carbidopa and levodopa, Rivastigmine tartrate, Rotigotine, Ferampanel, Apomorphine hydrochloride, Pramipexole and Others), Route of Administration (Oral, Sublingual, Parenteral  and Others), End- users (Hospitals, Homecare, Specialty Clinics, Others), Geography (North America, South America, Europe, Asia-Pacific, Middle East and Africa) – Industry Trends & Forecast to 2026

Market Drivers

  • Increase in prevalence rate of parkinson’s disease worldwide
  • Exposure to certain toxin or change in environment may increase the parkinson’s disease
  • The launch of new products and research collaboration are the prime strategies to reinforce the market position
  • Growing in aging population as it affect most commonly in geriatric population
  • Increase in the rate of R&D initiatives is driving parkinson’s disease drug therapeutics market

Market Restraints

  • High cost involved in the treatment
  • Patent expiry from many companies and introduction of generic drugs is expected to restrain the growth if the market
  • Lack of awareness among the patient and physician about parkinson’s disease treatment

Buy this Report (Can be used by entire organization across the globe + Downloadable and Printable PDF + 30 + Countries) @https://www.databridgemarketresearch.com/inquire-before-buying/?dbmr=global-parkinsons-disease-market&pm

Key Developments in the Market:

  • In February 2018, Osmotica Pharmaceuticals plc received FDA approval for Osmolex ER (amantadine hydrochloride) which is an extended release tablet indicated for the treatment of parkinson’s disease and drug-induced extrapyramidal reactions in adult patients
  • In August 2017, Adamas Pharmaceuticals, Inc. received FDA approval Gocovri (amantadine) extended release tablet for the treatment of dyskinesia in patients with parkinson’s disease receiving levodopa-based therapy, with or without concomitant dopaminergic medications

Reasons to Purchase this Report

  • Current and future of global parkinson’s disease market outlook in the developed and emerging markets
  • The segment that is expected to dominate the market as well as the segment which holds highest CAGR in the forecast period
  • Regions/Countries that are expected to witness the fastest growth rates during the forecast period
  • The latest developments, market shares, and strategies that are employed by the major market players

Customization of the Report:

  • All segmentation provided above in this report is represented at country level

All products covered in the market, product volume and average selling prices will be included as customizable options which may incur no or minimal additional cost (depends on customization)

About Data Bridge Market Research:

Data Bridge Market Research set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavors to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process.

Contact:

Data Bridge Market Research

US: +1 888 387 2818

UK: +44 208 089 1725

Hong Kong: +852 8192 7475

Email: Corporatesales@databridgemarketresearch.com

Back to top button